Clinical trial
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
NCT00493857 · YM BioSciences, Industry · Terminated
Key facts
| NCT number | NCT00493857 |
|---|---|
| Title | Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer |
| Official title | A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer |
| Lead sponsor | YM BioSciences, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Nimotuzumab Humanized Monoclonal Antibody, Nimotuzumab |
| Enrollment | 100 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 28, 2007 |
| Last update posted | Nov 17, 2008 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: